Stevanato Group Reports Solid 2025 Results, Sees Continued Momentum in 2026

Biopharmaceutical and Diagnostic Solutions segment drives growth, GLP-1 therapies a key focus

Published on Mar. 6, 2026

Got story updates? Submit your updates here. ›

Stevanato Group reported solid financial results for fiscal 2025, with total revenue increasing 9% at constant currency driven by double-digit growth in its Biopharmaceutical and Diagnostic Solutions (BDS) segment. The company's High-Value Solutions, including its Nexa syringe platform, were the primary drivers of 160 basis points of gross margin expansion. Looking ahead to 2026, Stevanato expects continued momentum, forecasting mid-teens growth in GLP-1 revenue and double-digit BDS growth, though the engineering segment is expected to decline.

Why it matters

Stevanato's performance highlights the growing demand for high-value pharmaceutical packaging solutions, particularly related to GLP-1 therapies for diabetes and obesity. The company's ability to navigate capacity constraints and invest in new facilities positions it well to capitalize on these market trends. However, the expected decline in the engineering segment underscores the challenges of managing a diversified business model.

The details

In Q4 2025, Stevanato reported a gross margin of 30.9%, up 120 basis points, driven by favorable product mix, improvements at its new Latina and Fishers facilities, and better vial market utilization. Operating margin was 20.2%, and net profit totaled EUR 47.6 million. For the full year, the company's Nexa syringe platform was the fastest-growing product, driven by strong GLP-1 demand, which represented 19-20% of total revenue and grew over 50% year-over-year. Stevanato expects GLP-1 revenue growth in the mid-teens in 2026, though capacity constraints remain a factor. The company is also gaining traction in other injectable biologics, with biologics now representing 41% of BDS revenues, up from 34% in 2024.

  • Stevanato reported full-year 2025 results on March 6, 2026.
  • The company expects commercial activities to begin at its Fishers, Indiana facility at the end of 2026 or early 2027 for a key U.S. customer device program.

The players

Franco Stevanato

Chairman and CEO of Stevanato Group.

Stevanato Group

A global provider of primary packaging solutions and related services for the pharmaceutical and biotech industries, specializing in the design, development and manufacturing of glass drug containers, advanced inspection systems, and assembly equipment.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee (Instagram)

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

This case highlights growing concerns in the community about repeat offenders released on bail, raising questions about bail reform, public safety on SF streets, and if any special laws to govern autonomous vehicles in residential and commercial areas.